GlassScriptPhysician profile
Jonathan Isaac Gotfried
NPI 1548556392
$34,259.63
in general payments reported to CMS, 2019-2025
31 companies · $5,229 in 2025
The $5,229 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $1,333 · 2021: $6,002 · 2022: $3,912 · 2023: $5,239 · 2024: $12K · 2025: $5,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,700 · Food and Beverage: $7,963 · Consulting Fee: $5,575 · Education: $24.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,700.00 |
| Food and Beverage | $7,962.83 |
| Consulting Fee | $5,575.00 |
| Education | $24.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,934.39 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $9,173.25 | 2024-2025 | Voquezna |
| Abbvie INC. | $3,474.70 | 2020-2025 | |
| Redhill Biopharma INC. | $1,926.22 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,888.96 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,040.10 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $905.12 | 2020-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $815.34 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $602.75 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $420.91 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $370.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $357.86 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $351.18 | 2024-2025 | Omvoh |
| Pfizer INC. | $315.21 | 2021-2025 | |
| Genzyme Corporation | $297.41 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $250.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $197.75 | 2022-2024 | |
| Gilead Sciences, INC. | $154.10 | 2021-2025 | Epclusa |
| Daiichi Sankyo INC. | $141.90 | 2022-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $134.62 | 2021-2023 | Rebyota |
| Ardelyx, INC. | $133.39 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $83.57 | 2021-2023 | |
| Sandoz INC. | $79.31 | 2023-2025 | Hyrimoz |
| Novo Nordisk INC | $38.74 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $33.60 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.53 | 2022-2023 | Sutab |
| Amgen INC. | $30.77 | 2021 | |
| Celltrion USA INC. | $30.24 | 2024 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.16 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $18.04 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gotfried listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.